How to Validate Predictive Immunohistochemistry Testing in Pathology? A Practical Approach Exploiting the Heterogeneity of Programmed Death Ligand-1 Present in Non-Small Cell Lung Cancer

Thunnissen Erik

首页> 外文期刊>Archives of pathology & laboratory medicine >How to Validate Predictive Immunohistochemistry Testing in Pathology? A Practical Approach Exploiting the Heterogeneity of Programmed Death Ligand-1 Present in Non-Small Cell Lung Cancer

【24h】

How to Validate Predictive Immunohistochemistry Testing in Pathology? A Practical Approach Exploiting the Heterogeneity of Programmed Death Ligand-1 Present in Non-Small Cell Lung Cancer

机译：如何在病理学中验证预测免疫组织化学测试？一种实践方法，利用非小细胞肺癌中的编程死亡配体-1的异质性

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Archives of pathology & laboratory medicine》 |2019年第1期|共2页
作者
Thunnissen Erik;
展开▼
作者单位

Vrije Univ Amsterdam Med Ctr Dept Pathol De Boelelaan 1117 NL-1081 HV Amsterdam Netherlands;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类病理学;
关键词

相似文献

外文文献
中文文献
专利

1. How to Validate Predictive Immunohistochemistry Testing in Pathology? A Practical Approach Exploiting the Heterogeneity of Programmed Death Ligand-1 Present in Non-Small Cell Lung Cancer [J] . Thunnissen Erik Archives of pathology & laboratory medicine . 2019,第1期

机译：如何在病理学中验证预测免疫组织化学测试？一种实践方法，利用非小细胞肺癌中的编程死亡配体-1的异质性
2. Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry：could it be predictive and/or prognostic in non-small cell lung cancer? [J] . Mari Mino-Kenudson 癌症生物学与医学（英文版） . 2016,第002期

机译：免疫组织化学程序性细胞死亡配体1（PD-L1）表达：在非小细胞肺癌中是否可以预测和/或预后？
3. Comparative study of programmed cell death ligand-1 immunohistochemistry assays using 22C3 and 28-8 antibodies for non-small cell lung cancer: Analysis of 420 surgical specimens from Japanese patients [J] . Tomohito Saito, Koji Tsuta, Mitsuaki Ishida, Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2018,第期

机译：使用22C3和28-8抗体对非小细胞肺癌抗体进行编程的细胞死亡配体-1免疫组织化学测定的对比研究：日本患者420例外科手术标本分析
4. A proteomic signature of relapse-related death predicting clinical outcome in human non-small cell lung cancer [C] . Kiyoshi Yanagisawa M.D., Shuta Tomida, Yukako Shimada, ASMS Conference on Mass Spectrometry and Allied Topics . 2006

机译：复发相关死亡的蛋白质组学特征预测人非小细胞肺癌临床结果
5. The cost effectiveness of screening for early stage lung cancer and the testing and treatment of molecular subgroups among non-small cell lung cancer patients in the province of ontario, canada [D] . Thao, Mallory. 2014

机译：加拿大安大略省非小细胞肺癌患者早期肺癌筛查的成本效益及分子亚群的检测和治疗
6. Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer? [O] . Mari Mino-Kenudson 2016

机译：免疫组织化学程序性细胞死亡配体1（PD-L1）表达：在非小细胞肺癌中是否可以预测和/或预测预后？
7. Assessment of programmed cell death ligand-1 expression with multiple immunohistochemistry antibody clones in non-small cell lung cancer [O] . Chen Pang, Limei Yin, Xiaojuan Zhou, 2018

机译：用多个免疫组织化学抗体克隆在非小细胞肺癌中评估程序化细胞死亡配体-1表达的评估

How to Validate Predictive Immunohistochemistry Testing in Pathology? A Practical Approach Exploiting the Heterogeneity of Programmed Death Ligand-1 Present in Non-Small Cell Lung Cancer

著录项

相似文献

相关主题

期刊订阅